The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II dose expansion of TH-302 in combination with doxorubicin in soft-tissue sarcoma.
L. D. Cranmer
Consultant or Advisory Role - Threshold Pharmaceuticals (U)
Research Funding - Threshold Pharmaceuticals
K. N. Ganjoo
No relevant relationships to disclose
D. Adkins
No relevant relationships to disclose
D. R. Reed
No relevant relationships to disclose
S. H. Okuno
No relevant relationships to disclose
J. E. Butrynski
No relevant relationships to disclose
D. A. Rushing
No relevant relationships to disclose
G. A. Lorente
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
S. Kroll
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
S. P. Chawla
No relevant relationships to disclose